Bioverativ (NASDAQ: BIVV) is one of 284 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Bioverativ to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, dividends, valuation and earnings.


This table compares Bioverativ and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bioverativ 40.44% 69.03% 40.94%
Bioverativ Competitors -5,592.19% -432.91% -40.69%

Insider & Institutional Ownership

93.5% of Bioverativ shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Bioverativ and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bioverativ $887.40 million $439.60 million 11.98
Bioverativ Competitors $286.20 million $34.74 million 137.58

Bioverativ has higher revenue and earnings than its competitors. Bioverativ is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations for Bioverativ and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bioverativ 1 8 6 1 2.44
Bioverativ Competitors 809 3181 11526 230 2.71

Bioverativ currently has a consensus target price of $60.36, indicating a potential upside of 23.15%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.67%. Given Bioverativ’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Bioverativ has less favorable growth aspects than its competitors.


Bioverativ beats its competitors on 7 of the 11 factors compared.

About Bioverativ

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with's FREE daily email newsletter.